Organization
The Second Hospital of Shandong University, Jinan, China
3 abstracts
Abstract
Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): Primary analysis of a prospective, multicenter, response-adapted study.Org: Second Hospital of Shandong University, Jinan, China, Affiliated Hospital of Jining Medical University, Jining, China, Binzhou Medical University Hospital, Binzhou, China, Linyi Cancer Hospital, Linyi, China, Liaocheng People's Hospital, Liaocheng, China,
Abstract
Evaluation of early response in association with pathological response in patients with breast cancer receiving neoadjuvant chemotherapy.Org: Second Hospital of Shandong University, Jinan, China, The Second Hospital of Shandong University, Jinan, China,
Abstract
Huaier granules for hepatocellular carcinoma recurrence after ablation: A multicenter prospective cohort study.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Beijing Youan Hospital, Capital Medical University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,